A carregar...
Pembrolizumab-Induced Mobitz Type 2 Second-Degree Atrioventricular Block
Pembrolizumab is a monoclonal antibody directed towards programmed cell death protein 1 (PD-1) and is an antineoplastic drug which has a growing variety of oncologic uses. Pembrolizumab is commonly associated with immune-related adverse events (IRAEs) but is infrequently noted to cause cardiotoxicit...
Na minha lista:
| Publicado no: | Case Rep Cardiol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7007942/ https://ncbi.nlm.nih.gov/pubmed/32047674 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/8428210 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|